{
  "docId": "019de076-8183-75b8-8b2d-7503ba8c42ba",
  "docSlug": "f8cc3498a347f12db8c194c5955f1d44",
  "documentTitle": "Kymera | Investor Presentation Deck | 46 slides",
  "authorId": "kymera",
  "authorName": "Kymera Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 46,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "appendix_disclosure",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "Clinical trial safety data summary.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-8183-75b8-8b2d-7503ba8c42ba/28",
  "deckHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba",
  "deckJsonHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba.json",
  "deckAnchorHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "*all Gr 1; **no Gr 4 or Gr 5 related AEs",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d49b1eec-9ca3-495f-aef0-18be83ea7035",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "Overall, KT-333 well tolerated with primarily Gr. 1-2 AEs\n2 DLTs observed (Gr. 3 stomatitis, Gr. 3 arthralgia) both in LGL-L patients at DL5; No DLTs in solid tumor/lymphoma patients at any dose level\nLed to protocol amendment to assess safety/MTD in solid tumor and lymphoma patients separately from leukemic patients (LGL-L, T-PLL)\nSolid tumor/lymphoma- currently at DL5 with plan to continue dose escalation as planned\nLGL-L/T-PLL- currently at DL3 with max escalation to DL4\nMost common related AEs across all patients (n=29), n (%):\nStomatitis, 6 (21%)\nALT increase, 3 (10%)*\nAST increase, 2 (7%)*\nRelated Grade 3 AEs**: 1 pt each: Stomatitis, arthralgia, weight decreased",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6aaa2329-5649-4214-91c6-61a7dae4b435",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.34,
        "x": 0.33,
        "y": 0.04
      },
      "kind": "title",
      "text": "KT-333 Safety Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ee66544-0635-47e9-9275-95ec58df2c15",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 46,
      "from": 21,
      "beatId": "5b777767-ae99-4f1a-ab2a-67ed14bef3b5",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The deck concludes with a call to action, highlighting upcoming milestones and events.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}